GLP-1 Drugs Linked to 17% Drop in Worker Sick Leave, Study Finds

A U.S. government study published by the National Bureau of Economic Research found that patients using GLP-1 drugs, such as Ozempic and Wegovy, took 17% less long-term sick leave compared to non-users. The study analyzed data on employee absenteeism, highlighting potential cost savings for both workers and employers. Long-term sick leave was defined as illness-related absences exceeding a certain duration. The findings suggest that these medications, originally developed for diabetes and weight management, may have broader economic benefits by reducing workforce disruptions. Researchers noted that the reduction in sick leave could translate into significant productivity gains for companies.

Global Impact

Economically, the study underscores the potential for GLP-1 drugs to reduce healthcare costs and improve labor productivity, particularly in developed economies with high obesity and diabetes rates. Socially, it could accelerate adoption of these drugs as a preventive health measure, shifting public perception from weight-loss aids to essential health tools.